393 related articles for article (PubMed ID: 16271726)
1. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Mallinckrodt CH; Prakash A; Andorn AC; Watkin JG; Wohlreich MM
J Psychiatr Res; 2006 Jun; 40(4):337-48. PubMed ID: 16271726
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine in the treatment of major depressive disorder: an open-label study.
Hudson JI; Perahia DG; Gilaberte I; Wang F; Watkin JG; Detke MJ
BMC Psychiatry; 2007 Aug; 7():43. PubMed ID: 17725843
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
Bailey RK; Mallinckrodt CH; Wohlreich MM; Watkin JG; Plewes JM
J Natl Med Assoc; 2006 Mar; 98(3):437-47. PubMed ID: 16573311
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Boulenger JP; Loft H; Olsen CK
Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
Detke MJ; Lu Y; Goldstein DJ; McNamara RK; Demitrack MA
J Psychiatr Res; 2002; 36(6):383-90. PubMed ID: 12393307
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
15. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder.
Whitmyer VG; Dunner DL; Kornstein SG; Meyers AL; Mallinckrodt CH; Wohlreich MM; Gonzales JS; Greist JH
J Clin Psychiatry; 2007 Dec; 68(12):1921-30. PubMed ID: 18162024
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.
Lewis-Fernández R; Blanco C; Mallinckrodt CH; Wohlreich MM; Watkin JG; Plewes JM
J Clin Psychiatry; 2006 Sep; 67(9):1379-90. PubMed ID: 17017824
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
18. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
Fava M; Detke MJ; Balestrieri M; Wang F; Raskin J; Perahia D
J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
20. Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses.
Dunner DL; Wohlreich MM; Mallinckrodt CH; Watkin JG; Fava M
Curr Ther Res Clin Exp; 2005 Nov; 66(6):522-40. PubMed ID: 24678074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]